Please login to the form below

Not currently logged in
Email:
Password:

Amgen’s Joseph Turgeon joins Spectrum as SVP sales and commercial operations

Joins fellow former Amgen employee Ken Keller

Spectrum Pharmaceuticals has appointed former Amgen executive Joseph Turgeon to senior VP sales and commercial operations.

In his new role, Turgeon will have responsibility for the commercialisation and sales of Spectrum's complete portfolio, which includes cancer treatments Fusilev (levoleucovorin), Folotyn (pralatrexate injection) and Zevalin (ibritumomab tiuxetan).

Turgeon has strong pedigree in the oncology market, having most recently served as VP sales, oncology at Amgen, where he led the launch of four new drugs and oversaw an increase in annual revenue from $2bn to more than $6bn.

He is the second major figure to move from Amgen to Spectrum in recent months following the appointment of Ken Keller as chief operating officer in September this year.

”The addition of Mr Turgeon following appointment of Mr Keller earlier this year is part of a planned strategy for expedited growth of Spectrum Pharmaceuticals,” Rajesh Shrotriya, chair, president and CEO of Spectrum Pharmaceuticals.

“With three anticancer drugs on the market now bringing nearly $300m in pro forma revenue and nearly ten drugs in clinical development, we are committed to strong growth in the next five years.”

In addition to Turgeon's appointment, Spectrum also announced that the company's chief commercial officer Jim Shields is to retire due to health reasons. He will continue to serve Spectrum in an advisory role.

31st October 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Limited

Lucid are specialists committed to delivering excellent medical education that changes clinical practice. Our confidence in understanding therapy areas, together...

Latest intelligence

More of the same: The importance of strategic communications planning for biosimilar entry
GCI Health's Hannah Morris considers the importance of strategic communications planning for biosimilar entry, a market anticipated to deliver between €8-26bn in savings across the European Union by 2020....
Online Physician Communities
How can pharma realise the power of digital?
Firstly, by making it owned and driven by the most senior leadership team in the business...
Remapping the market: Does Pharma's global model need a shake up?
For patients, carers and professionals, wherever they are in the world, digital technology is inherent in their everyday lives. Digital is, so to speak, a global language. The success of...